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Abstract
Ovarian cancers remain a perplexing group of diseases that continue to raise 
questions over their etiology and clinical behavior. They are the most fatal of 
gynecological cancers. Despite a global lifetime risk of only 1–2%, they contribute 
the highest mortality and the lowest 5-year (overall) survival rate of just 35%. The 
three broad histological groups: epithelial, sex cord-stromal and germ cell cancers 
have different biologic behavior and may constitute different clinical disease enti-
ties. Of the eight subtypes in the epithelial group, high-grade serous are universally 
the most common and have the worst prognosis. Globally making 65–85% of all 
ovarian cancers, most of the focus on risk factors has been directed on the epithelial 
group but the importance of other primary malignancies cannot be overemphasized 
as a step towards understanding their etiology and clinical behavior. The normal 
ovary has none of the epithelia that produce the range of epithelial ovarian cancers 
or there is an obvious premalignant stage, symptoms are very vague, screening and 
early diagnosis are difficult and indeed unrewarding. No specific etiology is known 
for any of the histologic groups. However, commonly mentioned risk factors like 
increasing age, genetics, nulliparity, prolonged infertility, use of fertility drugs, 
high animal fat, obesity, endometriosis, polycystic ovary syndrome, previous his-
tory of cancer, use of hormone replacement therapy, pelvic inflammatory disease 
and smoking may not apply to all the subtypes, while factors like increasing parity, 
breast feeding, use of oral contraceptive pills, hysterectomy, tubal ligation and use 
of antioxidants may differ in the degree of protection they provide. There may also 
be geographical and probably racial variations in the relevance of some of the risk 
factors. Thorough understanding of the predisposing and protective factors of the 
various histologic subtypes is an important step understanding the disease and 
therefore improving treatment outcome or providing effective prevention.
Keywords: risk factors, ovarian cancers, histologic subtypes, variation
1. Introduction
Ovarian cancer (OC) is an important public health problem with a lifetime 
risk of 1–2%. Recent estimates indicate that 295,414 cases are expected in 2018 
with about 184,000 of victims dying from the disease [1]. This reflects an increase 
of over 54,000 cases in incidence and 32,000 cases in mortality compared with 
earlier figures [2, 3]. Public screening for ovarian cancer has been neither feasible 
nor beneficial due to a lack of most appropriate screening test for the range of 
malignancies produced by the ovary. Use of tumor markers is largely unreliable 
since different tumor markers are secreted by different histological varieties and up 
to 50% of early disease may be associated with insignificant rise of tumor markers 
[4, 5]. Besides tumor markers could be raised by non-malignant conditions as well 
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as other malignancies [6–8]. Cancers of the lung, pancreas, colorectal, breast and 
non-Hodgkin’s lymphomas are associated with a rise in CA125 [9, 10] which is also 
raised in benign conditions such as endometriosis, ovarian cyst, leiomyoma uteri 
and pelvic inflammatory disease [4, 8, 11]. Only 50% of early OC is associated with 
raised CA125 making it unreliable for early diagnosis. More than 75% of OC are 
diagnosed in late stages of disease [12–14] when prognosis is very poor. Screening 
did not reduce mortality in two large trials [12, 15].
The ovaries are totipotential in their ability to form wide histologic varieties of 
cancers with different biology, natural history and possibly mechanism of onset 
[16–18]. These heterogeneous tumors differ in their clinical behavior including 
response to treatment and prognosis. Knowledge of the cause or genesis of OCs is 
very scant and the available hypotheses do not explain observed disease phenomena 
[19, 20]. The uniqueness of OC in having no known premalignant stage, no reliable 
screening tool, very vague symptoms in early and advanced stages make identifica-
tion of at risk group important for prevention, early diagnosis and possibly as a step 
towards defining its etiology.
The World Health Organization classifies ovarian cancers based on histologic 
origins of the cells, as epithelial, sex cord-stromal and germ cell tumors [16, 21] 
(Table 1). The epithelial ovarian cancers are made up of eight histologic subtypes 
with different cellular origin, pathogenesis, gene expression and response to 
treatment [13, 16, 17]. The most common type, serous cyst adenocarcinoma with 
two distinct subtypes may be arising from the fallopian tube epithelium. The high 
grade serous accounts for 85% of the epithelial ovarian cancers and up to 80% of 
Histological
I. Epithelial tumors
A. Serous cyst adenocarcinoma
B. Mucinous Cyst adenocarcinoma
C. Endometrioid
D. Clear cell (mesonephroid)
E. Brenner’s
F. Mixed epithelial
G. Undifferentiated
H. Unclassified
II. Sex cord-stromal tumors
A. Granulosa
B. Androblastoma
C. Gynandroblastoma
D. Unclassified
III. Lipid cell tumors
IV. Germ cell tumors
A. Dysgerminoma
B. Endodermal sinus tumors
C. Polyembroyoma
D. Choriocarcinoma
E.  Teratoma
F. Mixed tumors
V. Gonadoblastoma
VI. Soft tissues not specific to the ovary
VII. Unclassified
VIII. Metastatic
Table 1. 
WHO histological classification for ovarian cancers.
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ovarian cancers generally [22]. It is the most challenging in terms of treatment 
outcome. Mucinous adenocarcinomas have cells similar to the cervical epithelium, 
endometrioid cancer cells resemble the endometrium, while Brenners tumors have 
transitional epithelium akin to that of the bladder [19].
The fimbriated end of the fallopian tube has morphologic and molecular simi-
larities with high grade serous ovarian cancers which also expresses TP53 signature 
suggesting that neoplastic process may be originating from tubal epithelium and 
shed into the ovary where aggressive neoplastic process proceeds [14, 19]. Low-grade 
serous ovarian cancers share similar histiogenesis but progress through a separate 
pathway and has different prognosis [18, 23, 24]. It represents less than 5% of the 
epithelial cancer [25].
The sex cord-stromal tumors are a heterogeneous group, which include several 
histologic subtypes (Table 1). Apart from adult granulosa tumor that affects 
women in their fifth decade, sex cord-stromal tumors mainly affect women in the 
second or third decade of life and account for about 5% of malignancies in women 
15–24 years [26]. Several subtypes are associated with genetic predisposition, 
including in patients with Peutz-Jeghers syndrome [27].
The germ cell tumors, which include dysgerminomas, immature teratoma, embry-
onal tumors and endodermal sinus tumors form only 1.5–5% of OC. Approximately 
one-third are dysgerminomas, another third immature teratomas and a further 
one-third include the rest three (embryonal tumors, endodermal sinus tumors, cho-
riocarcinoma and mixed cell types) [19, 28]. Malignant germ cell tumors of the ovary 
may be developing through similar pathways with testicular germ cell tumors but the 
ovarian have greater histological complexity than most solid somatic tumors.
This diversity in genesis may partly explain the observed differences in clinical 
behavior.
2. Hypothesis for ovarian carcinogenesis
Development of OC has remained a mystery since hypotheses advanced do not 
convincingly explain the observed phenomena. It is important to explain how other 
surface epithelia form aggressive primary neoplasm in a separate organ.
The ‘incessant ovulation’ theory explains that repetitive ovulatory micro trauma 
to the ovarian surface in association with the tubal epithelium results in carcinogen-
esis through mistakes in repair of the damaged surface epithelium [29, 30]. While 
this hypothesis partly explain serous cystadenocarcinoma, it fails to explain other 
subtypes in the epithelial group and does not offer plausible explanation for the 
germ cell tumors and the sex cord-stromal tumors.
The pituitary “gonadotropin hypothesis” indicates that high levels of estrogens 
and gonadotropins such as luteinizing hormone and follicle-stimulating hormone 
would over stimulate the ovarian epithelium causing increased proliferation and 
subsequent malignant transformation [31, 32].
The “inflammation hypothesis” proposes that factors such as endometriosis, 
pelvic inflammatory disease and other inflammatory conditions may stimulate 
cancer formation [31, 33].
These theories have failed to provide plausible genesis for ovarian cancer there-
fore new hypothesis have been proposed [19, 34].
Understanding a clear etiology is far from site, a thorough global analysis of 
the risk factors of the disease may be a good starting point to unraveling the etiol-
ogy and therefore an effective strategy towards disease control and prevention. It 
is however expected that the range of tumors may very well differ in risk factors 
and epidemiology.
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3. Predisposing factors
Predisposing and protective factors for ovarian cancers vary according to histo-
logic type [13, 18]. Although most studies concentrate on epithelial ovarian cancers, 
particularly serous cystadenocarcinoma, which tends to form the major global 
disease burden, risk factors to other histologic types are important prerequisite to 
their genesis and will be considered in this review.
4. Racial and geographical risk
Ovarian cancer is a cosmopolitan disease as it occurs in every geographical loca-
tion and in every race [1, 30]. Epithelial ovarian cancer is the commonest subtype all 
around the world with high-grade serous accounting for 60–85% of cases [22, 35–38].
Highest incidence of OC is found among white females in Northern and 
Western Europe and in North America with age adjusted incidence exceeding 
8.4/100,000 [1, 30]. Recent statistics from the US show a decline in incidence 
from 16.6/100,000 in 1985 to 11.8/100,000 in 2018 [39]. Incidence is also high in 
New Zealand and among Jewish women in Israel but low in Africa and Asia with 
estimated rates of <3/100,000 [37]. Japan, though reported to have low incidence is 
experiencing a rising trend in the disease of recent [40].
All regions of North America show higher incidence of invasive ovarian cancer 
among white women [41].
Within Europe too, there is difference in incidence and mortality across the region. 
Using WHO data base of 28 European countries from 1953 to 2000, Bray et al. reported 
Nordic countries, Austria, Germany and the United Kingdom to have the highest 
trend in the 1960s but the trend tended to decline over the recent years while Southern 
European countries showed an upward trend. Similarly, central and eastern European 
countries with hitherto low incidence are experiencing a rising over time [12, 35] . In 
the most recent 5-year period (2003–2007), the incidence of ovarian cancer was high-
est in Eastern/Southern Europe, followed by Northern Europe, and Western Europe 
[22] Asian sub region reports lower rates than Europe and America [2, 3].
South Eastern Asia have highest rate in the subcontinent and Eastern Asia has 
the lowest rate.
Migration to areas of high risk increases the risk of disease therefore cultural and 
dietary factors may be responsible for the observed difference. Japanese immigrants 
to the US have equivalent risk as natives [42].Racial variations in the incidence of 
ovarian cancer are best observed in the USA. Age adjusted incidence rate are higher 
in whites than in non-whites and Indians in the USA have lowest mortality from 
ovarian cancer. While Caucasian Americans have higher disease incidence, African-
Americans have 1.3 times higher disease mortality and lower survival rates even 
with equal access to care [43]. They also experienced poorer 5-year survival rates 
irrespective of stage of diagnosis [44, 45].
From the Surveillance Epidemiology and End Result (SEER)database (1992–
1998), AA experienced a fall in 5-year survival rates from 47.9 to 40.3%, while their 
Caucasian counterparts witnessed an improved survival from 40.7 to 45% in the 
same period. The observed disparities have been linked to interplay of socioeco-
nomic, environmental, genetic and epigenetic factors [43].
Determining the incidence of ovarian cancer in four US populations of het-
erogeneous racial-ethnic composition, Weiss and Paterson found 19–42% lower 
incidence among Japanese, Chinese, Hispano and black women compared with 
white women [44]. The observed difference is primarily due to lower rates of serous 
and papillary tumors. Chinese women also had decreased incidence of mucinous 
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tumors, while Hispano and black women had lower incidence of endometrioid-
clear cell tumors.
The incidence of non-epithelial cancers remains fairly constant between the 
races; especially germ cell tumors which has remained stable in incidence for three 
decades [44]. However, data from SEER suggest that the incidence of sex cord-
stromal tumors is significantly lower among white women compared with black 
women (0.18 vs. 0.35 per 100,000 person years; relative risk, 0.53; 95% confidence 
interval (95% CI): 0.42–0.67) [46].
OC rates from Africa though reported to be low must be considered in the 
background of health circumstances in the region of lack of cancer registries, poor 
utilization of health facilities and rudimentary statistics.
Ovarian cancer is reported to be more common in developed countries than 
developing nations but over the last three decades, ovarian cancer incidence has 
remained stable in high-risk countries, while an increasing trend has been reported 
in low-risk countries.
5. Age as a risk factor
Increasing age is a risk factor for ovarian cancer which is generally considered 
a disease of the older women. Globally, the annual incidence regardless of age is 
42 cases/100,000 women. Data from US SEER, ovarian cancer is rare before the 
age of 40 years and incidence rises steadily after the fifth decade to reach a peak at 
80–84 years, when the age specific incidence is 61.3/100,000 women. More than 
half of cases of ovarian cancers are diagnosed in women over 65 year [47].
In the United States, the annual incidence is 61.3 per 100,000 for women aged 75 
and 79 years.
In the UK, the overall incidence of a symptomatic ovarian cyst in a premeno-
pausal female being malignant is approximately 1:1000 increasing to 3:1000 at the 
age of 50 years although 1000 women under the age of 50 years develop ovarian 
cancer annually in the UK [48–50]. Most diagnose are other histologic subtypes 
like borderline tumors and germ cell tumors. EOC are generally reported to be 
uncommon in young premenopausal women in the UK [50]. Women aged 65 years 
and above make 64% of mortality from OC [47, 50]. Young premenopausal women 
are more commonly affected by germ cell tumors and borderline tumors in most 
reports from European literature [35, 51].
Similarly, a meta-database analysis of 5055 ovarian cancer patients of 4 pro-
spective phase III intergroup trials identified 294 (5.8%) patients under the age of 
40 years from European studies. Young age appeared a strong independent protec-
tive on overall incidence of EOCs as well as prognostic factor for PFS and OS [52].
The issue of age and ovarian cancer diagnosis may however be different among 
non-Europeans races. Reports from India show much younger age affected than 
most European papers for EOC. Murtha et al. reported increased risk after 35 years 
with peak at ages of 55–64 years. Saini et al. have reported mean age of 55 years Basu 
et al. had 48.8 ± 11.2 years while Mondel had 48 years and Jindal et al. had a mean of 
48 years. Malik from Pakistan found mean age for EOC to be 49.5 ± 13 years [53–57].
Mostafa et al. from Egypt reported a mean age of 47 years for epithelial ovarian 
cancers, with 1% of cases affecting women of 30 years and only 3% occurring in 
older women of 70 years [58].
From African subcontinent, findings contradict increasing age as a risk fac-
tor for EOC as reports show young premenopausal women to be mostly affected 
with serous cystadenocarcinoma, which is the most common histiotype. There is 
increasing report of rising incidence of ovarian cancer from Africa [38, 59–61]. 
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Most reports suggest EOC to be the commonest but predominantly seen in young 
premenopausal, generally parous women [38, 60, 61].
A global report by the International Federation of Gynecology and Obstetrics 
(FIGO) has noted that the highest incidence of ovarian cancer was moving towards 
a younger age group, although the majority of patients with epithelial cancer were 
more than 50 years in age [38].
It is interesting that high grade serous cyst adenocarcinoma remains the com-
monest variety while literature from USA, Europe, Israel and Australia find it in 
older women above 65 years, in Asia, the Arab world and Africa, it is observed in 
young premenopausal women. Research for this important difference is worthwhile.
Early menarche is considered a weak predictor of ovarian cancer risk and 
women whose menarche was earlier than 12 years are at increased risk of epithelial 
tumors [62, 63]. Meta-analysis of 22 case–control studies and 5 cohort studies has 
reported a statistically significant inverse association between menarcheal age and 
ovarian cancer risk (RR = 0.85; 95% CI: 0.75–0.97) [62], but this association is most 
significant in invasive serous and borderline tumors. In this respect, ‘incessant 
ovulation’ theory as possible cause of tumor genesis provides plausible explanation 
[30, 34]. No association was found when menarche begins after age 16 years. Late 
menarche has not been shown to be protective [64].
Women who experience natural late menopause are at increased risk [13, 34, 65]. 
Odds ratios for late natural menopause were reported as low as 1.19 and as high as 
1.25 (95% CI: 0.95–1.49) [65]. These findings may suggest that earlier menarcheal 
age and late natural menopause might increase risk of ovarian cancer by increasing 
a woman’s lifetime number of ovulations. Results from the Nurses’ Health Study 
(NHS) confirmed increased risk of endometrioid epithelial cancers with late natu-
ral menopause but not of serous or mucinous cancers (RR = 1.3, 95% CI: 1.04–1.22). 
Furthermore, the European Prospective Study into Cancer and Nutrition Cohort 
(EPIC) age at menopause >52 years was associated with increased risk compared 
with 45 years or less [66].
6. Infertility and use of ovulation induction drugs
Infertility either by itself or in association with some of its causes like endome-
triosis, is a risk factor and prolonged period of infertility is associated with higher 
risk [67].
A large cohort study, involving 54,362 women with infertility in the Danish 
fertility clinics (1963–1998) used parity specific cancer incidence and reported 
significantly increased from infertility (1.46, 95% CI: 1.24–1.71) [68].
Whittemore et al. analyzed 12 US case–control studies between 1957 and 1985, 
with 2197 cases of ovarian cancer and 4144 controls and confirmed higher risk in 
nulligravid subfertile women compared with controls [20].
However, study by Ness with 5207 cases of ovarian cancer and 7705 controls 
found only a weak association between infertility and epithelial ovarian cancer (OR 
1.16, 95% CI: 1.02–1.31) [69].
Drug treatment of infertility may further increase risk as untreated infertile 
nulliparous women have 1.5–2-fold risk, while women who received treatment and 
failed to conceive have even higher risk [70].
Use of ovulation induction agents like clomiphene citrate, gonadotropins are 
associated with three times higher general population [69] particularly prolonged 
use of clomiphene (for more than 12 cycles). This is associated with rise in risk for 
invasive and borderline cases by about 11.1-fold compared with infertile women 
with no clomiphene use [67].
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Use of gonadotropins is also associated with increased risk [31, 70]. There are, 
however, a number of studies that show no increased risk of OC with use of ovula-
tion induction agents [71].
However, studies that report increased risk do of borderline tumors only not 
high grade serous.
7. Genetic factors
More than one-fifth of OC cases are hereditary from highly penetrant autosomal 
dominant genetic susceptibility [72]. Although accounting for only a limited num-
ber of cases, heredity is a strong risk factor for OC. The lifetime risk of a woman 
who has a first degree relative with OC is 5% compared with 1.4% in a woman 
without. The risk rises to 7% if two members of the family are affected [73]. These 
rate has been thought to be a probable underestimate as a British study has shown 
that where two close relatives (not necessarily first degree) are affected, the risk 
may be as high as 30–40% [73, 74]. The risk for confirmed carriers of BRCA at the 
age of 70 may be as high as 63% [73, 75]. Ovarian cancer in a first degree relative, 
has been shown to be a strong positive indicator of early onset epithelial cancer and 
positively associated with non-mucinous tumors [76].
The three main clinical types of genetic ovarian cancers include site-specific, 
hereditary breast and/or ovarian cancer (HBOC) and hereditary non-polyposis 
colorectal cancer (HNPCC) or Lynch II syndrome [77].
The first two syndromes are related to inheritance of BRCA1 and BRCA 2. 
Patients with HNPCC have inherited mismatch repair genes (MLH1, MLH2, MLH6, 
PMS1, PMS2 and possibly some other yet unidentified genes).
BRCA genes are common in the Ashkenazi Jewish population where 29–41% of 
ovarian cancer is believed to be secondary to inheriting one of three founder muta-
tions in BRCA1 and BRCA2, against 10% in non-Ashkenazim [78].
BRCA 1 gene is an oncosuppressor gene located at chromosome 17q, it partici-
pates in chromatin remodeling and crucial steps in cell cycle [79].
OC associated with BRCA mutations are diagnosed at a younger age and are of 
high-grade serous type. In one study, the average age at diagnosis of OC in BRCA1 and 
BRCA2 mutation carriers was 52 and 62 years, respectively [77, 80]. BRCA mutations 
do not seem to play a significant role in the development of mucinous or borderline 
ovarian tumors. The BRCA associated OCs also tend to have better clinical outcome 
with longer overall survival and recurrence-free interval than sporadic cancers [77].
There is no standard clinical definition of hereditary breast and ovarian cancer 
syndrome but affected families may be identified from:
• Several cases of breast cancer diagnosed before the age of 50 years.
• One or more cases with ovarian cancer in the family.
• One or more relatives with both breast and ovarian cancer.
• The presence of a BRCA1 or BRCA 2.
• However, many women without a family history may still have a gene mutation 
associated with their BRCA1 or BRCA 2.
Lynch syndrome (LS) or hereditary non-polyposis colon cancer (HNPCC) refers 
to germline mutations in MMR genes (MLH1, MSH2, MSH6, MLH3 and PMS2), 
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which lead to the loss of expression of one of the MMR proteins. Clinically, LS is asso-
ciated with higher risk of colorectal cancers that have specific predilection to location 
proximal to splenic flexure [72, 81]. Confirmed case of Lynch syndrome is associated 
with 6–10% life time risk of OC of early onset. MLH1 carriers are often diagnosed of 
ovarian cancer at average age of 52 years and MLH2 carriers at age of 45 years [82, 83].
HNPCC syndrome is also associated with cancers of the stomach, small bowel, 
hepatobiliary tract, pancreas, renal pelvis, ureter, breast, prostate and brain (partic-
ularly glioblastoma) [72, 84]. The OCs associated with LS are commonly endome-
trioid and clear cell varieties [82, 85] and tend to be diagnosed at a relatively early 
stage with high stage-specific survival rate compared with non LS type [86, 87].
The Li-Fraumeni syndrome is an autosomal dominant syndrome characterized 
by heterozygous germline mutation in TP53. It is the most frequently mutated gene in 
human cancer thus the syndrome is associated with development of multiple cancers 
at young age. About 50% will develop first tumor at age of 30 years [88] and up to 
35% will develop multiple tumors in their lifetime [89]. Li-Fraumeni syndrome asso-
ciated OC, though not the most common but tend to occur at around 39.5 years [90].
Peutz-Jeghers syndrome(PJS) is a rare autosomal dominant condition occur-
ring in 1 in 25,000–30,000 livebirths [91] characterized by benign hamartomatous 
intestinal polyps with very low tendency to malignancy, cutaneous lesions increased 
risk of OC in addition to cancers of breast, colon, rectum, pancreas, stomach, 
testicles and lungs. Tumor suppressor gene STK11(LKB1), located on chromosome 
19p13.3 is responsible for this syndrome. OC risk is as high as 18–21% [92]. The 
ovarian cancers associated with this syndrome are sex cord tumor with annular 
tubules (SCTATs) in addition to a range of other gynecological cancers [92, 93].
Mutations in double strand breaks repair system like CHEK2, RAD51, BRIP1 and 
PALB2 are also associated with increased risk of various types of ovarian cancer 
[89, 94]. To date, more than 16 genes are known to be involved in the mechanism of 
hereditary ovarian tumorigenesis and new ones are being discovered [77, 95].
8. Use of perineal talc
Talc, a metamorphic mineral composed of silicon, magnesium and oxygen, is a 
common component of genital powders. Applied by women for moisture absorption 
to prevent perineal chafing and rashes, talc has similarities to and co-occurs with 
asbestos in its natural form, which is a known carcinogen [96, 97]. Contamination 
of talc with asbestos was hypothesized to have a causal role in ovarian carcinogenesis 
[13, 98]. The finding of talc materials in ovarian cancer specimens supports this 
argument [99]. The International Agency for Research on Cancer(IARC) in 2006, 
classified genital talc use as possibly carcinogenic to humans based on evidence from 
epidemiologic studies (carcinogen group 2B) [100, 101].
Although the biological basis of talc carcinogenicity is not clear, direct physical 
contact with ovarian epithelium may cause chronic inflammation and retrograde 
transport of talc particles through the reproductive tract as suggested by some 
workers may occur [98]. An immune mechanism may also be the case.
Several case–control studies report association between perineal talc use and 
ovarian cancer and data from Women Health Initiative support this association also 
support this fact [98, 102–104]. Furthermore, a prospective study has confirmed 
association with serous cystadenocarcinoma and talc use. However asbestos-free talc 
has been in use in cosmetic products at least in most developed countries and later 
case–control studies show no association between use of talc and ovarian cancer [104]. 
Other case–control studies found increased risk by 92% that is a relative risk of 1.92 
[98]. A study by Cook et al. reported 1.60 relative risk of ovarian cancer with use than 
non-use. This is an increase of 60%. Finally, a meta-analysis of about 20 published 
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works reported 35% increased risk of cancer in women who used talc [102]. Scientific 
evidence has weighed heavily against the makers of talc products who recently lost 
over 4 billion dollars to a group of 22 women who developed ovarian cancer following 
talc use adding a court evidence to ovarian carcinogenesis by talc [105].
9. Diet and ovarian cancer
Diet has been directly or indirectly related to risk of ovarian cancer though very 
few studies specify the histologic subtype in relation to dietary types. Diet may 
be modifying the risk of ovarian cancer through effect on endogenous hormones, 
antioxidant activity or other anticarcinogenic mechanisms. There is however a 
unanimous finding of reduced incidence of ovarian cancer with higher intake of 
vegetables especially for epithelial ovarian cancer [106–111]. The average finding 
is a reduction of risk by about more than 50%. High dietary fiber, carotenoids total 
ligands and phytochemicals are associated with reduced risk [112].
Dairy products have received conflicting results. While over the years, studies 
showed no associations between dairy intake and ovarian cancer of any type 
[113, 114]. Faber et al. using the Danish population-based case–control studies 
reported increased risk especially with milk and lactose but decreased risk with 
cheese [115]. An interesting study by Merritt et al. using data from New England 
case–control study examined including histological subtypes and tumor aggression 
in relation to intake of dairy foods. They reported decreased risk of serous borderline 
and mucinous cancer with higher intake of calcium and vitamin D. High Vitamin D 
intake was also found to be inversely related to serous borderline and endometrioid 
cancers [116]. Merritt et al. found no evidence between lactose intake and risk of 
ovarian cancer [116].
High intake of total fat, animal fat, cholesterol and saturated fats may be associ-
ated with increased risk. Meta-analysis of 16 independent studies reported significant 
increase in risk of ovarian cancer with high intake of total saturated and trans fats 
with serous cancers being especially susceptible to dietary fats than other histologic 
subtypes [117, 118]. Huncharek and Kupelnick reported a RR of 1.70 or an increased 
risk of 70% in patients with high fat intake [117], however Bertone et al. found no 
association with intake of fats alone but associated increased with when combined 
with high intake of eggs [119]. High intake of eggs alone are reported to increase 
risk [111, 120]. This effect has been linked to high dietary cholesterol which may be 
increasing risk of ovarian cancer through increased circulating estrogens [111, 121].
Although the link between ovarian cancer and high intake of meat has been 
controversial with some studies finding no association [122], majority report positive 
association between high intake of red and processed meat with epithelial ovarian 
cancer, while poultry and fish have either no relative increase or observed reduction in 
risk [123–126].
High alcohol consumption has been studied in reasonable depth and only few 
studies show no association [127] while others show a reduction in risk with mini-
mal and moderate intake of alcohol [128, 129]. The observed phenomenon may be 
due to the anti-oxidants in the wine and alcohol rather than the alcohol itself [130].
While tea consumption has not been associated with risk of ovarian cancer, coffee is 
associated with modest reduction of risk [131, 132].
High dietary intake of B carotene is reported to be protective against epithelial 
ovarian cancer; in a meta-analysis of over 3782 subjects, a modest 16% reduced risk 
was found [133]. Supplemental selenium (>20 μg daily) is associated with 30% risk 
reduction [134]. This fact, however, does not support use of selenium as a preven-
tive strategy [135]. These antioxidants may be reducing risk by limiting oxidative 
stress to the ovarian epithelium.
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The effect of vitamin D, particularly D3, has been of interest because of its abil-
ity to cause apoptosis of cancer cells in vitro and the demonstrated increased risk of 
ovarian cancer in vitamin D deficient Europeans [136], more research is necessary 
to define clinical implication of these findings as some researchers propose supple-
mentation of vitamin D for preventive purposes [137].
10. Smoking
Association between cigarette smoking and ovarian cancer is not as clear as 
other cancers like lungs oropharynx and lungs that are very well documented [138]. 
However, metabolites of nicotine which are potent hydrocarbons and carcinogens 
like cotidine and benzopyrene have been isolated in follicular fluid and OC has been 
induced in rodents with cyclical hydrocarbons [139].
Cigarette smoking is associated with increased risk of mucinous ovarian cancers 
[140–143] but the effects on other histologic types is less clear. A Norwegian study, 
found increased risk of invasive borderline cancers in addition to mucinous [140]. 
Smokers however have a deficit of endometrioid tumors.
Survival of patients who smoke is also found to be worse than that of non-
smokers [142, 144]. Studies have confirmed the increased risk of mucinous epi-
thelial cancers in smokers to be directly proportional to the pack-years of smoking 
[145, 146]. A twofold increased risk of mucinous epithelial cancers is the generally 
observed phenomenon [141, 143, 146], but could be up to fourfold increase in 
women who have smoked for 40 years or more [146].
There is a suggestion however that with the deficit in clear cell and endometrioid 
cancer and despite the increase in borderline and mucinous cancer smoking may 
not be associated with overall increase in ovarian cancer mortality [144].
11. Endometriosis and risk of ovarian cancer
OC prevalence in women with endometriosis is higher than the general popula-
tion 1.32–1.9 [147]. A recent systemic review agrees with this modest increase in 
risk of endometrioid, borderline and clear cell cancers with endometriosis [148]. 
Some reports suggest about two to threefold increase in risk [149]. This association 
between endometriosis and OC is not a proof of causality for the histiotypes.
It is more common in patients with longstanding or recurrent endometriosis and 
removal of endometrioma is not preventive towards development of OC [150]. The 
increased risk might be due to high estrogen concentration or due to gene mutations 
caused by oxidative stress due to iron in the endometriotic cyst [151].
12. Polycystic ovarian syndrome
PCOS is the commonest endocrine disease in women of reproductive age with 
incidence of about 20% [152]. Associated with infertility, obesity and abnormal 
gonadotropin secretion, PCOS is associated with 2.5-fold increased risk of epithelial 
ovarian cancer [153]. The risk of ovarian cancer in women with PCOS is greatest in 
lean women and those who never used oral contraceptive pills [153, 154].
A systemic review involving eight studies and a meta-analysis found increased 
incidence of borderline serous cancer in patients with PCOS [155]. Proteomic 
biomarkers for identification of patients with PCOS who are at increased risk of 
ovarian cancer may be useful for early diagnosis but the clinical use of these mark-
ers need further verification [156].
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13. Pelvic inflammatory disease
Inflammation has been implicated in ovarian carcinogenesis but studies inves-
tigating the association between pelvic inflammatory disease (PID) and ovarian 
cancer risk are few and inconsistent with some studies reporting positive associa-
tion [157, 158] and others excluding such association [159, 160]. A pooled reanalysis 
of 13 studies reported increased risk of borderline ovarian tumors in women who 
had multiple episodes of pelvic inflammation [157]. This association may be pro-
nounced among Asian women [158]. Rasmussen et al. in a population-based cohort 
study recently reported increase in risk of serous ovarian cancer in patients with 
PID [157]. Therefore we can conclude that repeated episodes of PID is associated 
with statistically significant risk of borderline and serous cancers but not non-
epithelial cancers which have been found not to be associated with PID [158].
14. Hormone replacement therapy (Hrt) and risk of ovarian cancer
Women who use menopausal hormone therapy are at an increased risk for 
ovarian cancer. A review and meta-analysis of data published between 1966 and 
2006 concluded that current use of postmenopausal hormone therapy (HT) 
increased the risk of ovarian cancer by 30% compared with never use of HT [161]. 
Estrogen alone was thought to confer higher risk than combined estrogen and 
progesterone which is refuted by finding from data from million women study  
[162, 163]. Recent studies indicate that using a combination of estrogen and pro-
gestin for 5 or more years significantly increases the risk of serous and endometri-
oid OC in women with intact uterus, but for women who have had hysterectomy, 
10 or more years of use is associated with increased risk [161, 164, 165]. In a recent 
pooled analysis of 52 epidemiological studies, the risk of serous cancer was 51.4% 
and that of endometrioid was 48.6% [164]. The increase has been interpreted to 
mean one extra OC in 1000 users and one extra mortality in 1700 user [166]. There 
is more risk with prolonged use irrespective of the type of HRT, regimes used or 
mode of administration.
15. Obesity
Obesity may be increasing risk of ovarian cancer significantly [166–168]. Obese 
women (BMI > 30 kg/m2) who have not used menopausal hormone replacement 
therapy (MHR) had 25–80% increased risk compared with women with normal 
BMI (18.5–24.9) no relationship between BMI and OC in women with family 
history. Obesity is associated with an almost 80% higher risk of ovarian cancer in 
women 50–71 who had not taken hormones after menopause. For women who have 
not used HRT, evidence shows risk of ovarian cancer to increase by 10% with every 
5 kg/m2 increase in BMI (Collaborative Study). Higher BMI in young adulthood is 
reported to increase risk of premenopausal ovarian cancers [167].
Evidence from meta-analysis of 14 studies shows that slightly worse survival 
in obese women with ovarian cancer compared to non-obese women (pooled 
HR = 1.17, 95% CI: 1.03–1.32) [169].
Obesity may be increasing this risk for ovarian cancer through increasing 
inflammatory biomarkers and increase in hormonal factors especially androgens 
which is important in development of mucinous tumors [170].
Histologic subtypes associated with obesity include low-grade serous, mucinous 
tumors and endometrioid cancers. No association was found between high grade 
serous and obesity therefore reducing BMI is unlikely to reduce the incidence of 
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high grade serous cancers [171]. Moreover, obese women with HGSC have poorer 
outcome than their non-obese counter parts [172].
Recent systemic review of 43 studies involving more than 3 million women 
concludes that the evidence is inconsistent that obesity is a definite risk factor for 
ovarian cancer [173]. This finding may be due to the dominance of HGSC which risk 
is not affected by obesity.
16. Protective factors that reduce risk of ovarian cancer.
16.1 Pregnancy
Pregnancy is thought to be protective against ovarian cancer [13, 47, 65]. 
Pregnancy whether uncompleted or term confers a protective benefit against epi-
thelial ovarian cancer. Increasing parity is associated with a reduction in the risk of 
ovarian cancer [36, 63, 65, 174]. Pregnancy may be protective against all histological 
subtypes. A Swedish study has reported reduced risk for epithelial, stromal and 
germ cell tumors, but less consistent decrease in borderline cancers [63].
However, it appears that the protective effect of pregnancy (and breast feeding) so 
called reproductive factors, may be more significant in the West, parts of the US and 
among Jewish women as reports of ovarian cancer of all histologic subtypes in parous 
women in developing countries is so widespread and requires further research [38, 53, 55, 
57, 59, 60]. The significance of this phenomenon is that the protective effect of pregnancy 
may be lost in the face of other more important risk factors that need to be defined.
All theories of ovarian carcinogenesis are not plausible explanation for the 
observed protective effect of pregnancy, therefore pregnancy-induced clearance of 
malignant cells has been proposed [63] which must to be case in all races to be an 
acceptable hypothesis.
16.2 Breastfeeding
Breast feeding exerts a strong protective effect with long-term breast feeding 
being more protective especially against epithelial cancers [175]. The mecha-
nism may be by suppression of gonadotropins through unovulation, resulting 
in depressed production of plasma estradiol and unovulatory cycles [65, 176]. 
Breastfeeding also reduces the levels of gonadotropins, especially luteinizing 
hormone [176], which may be causal mechanism for ovarian carcinogenesis [177].
Meta-analysis of 12 US studies and 9 studies from developed countries showed 
an inverse association between breastfeeding and ovarian cancer risk [175]. Women 
who breast fed for up to 6 months showed duration-dependent benefit with women 
who breastfed for long having more protection. Breast feeding may be reducing risk 
of epithelial cancers by up to 30% compared with women who did not breast feed.
16.3 Oral contraceptives
The use of oral contraceptives decreases the risk of developing OC and the ben-
efit may be enjoyed up to 25–30 years after stopping the pill [178, 179]. COCP use 
is associated with about a 40–50% lower risk compared with never use [178, 180]. 
Length of pill use appears to influence the degree of protection, with a relative risk 
of 0.4 for more than 5 years reported in pooled European and US studies [178, 181].
The protective benefit may be experienced even in high risk women though there 
is not enough evidence for use of the pill for chemoprophylaxis [180, 182, 183]. 
Women who use the pills for more than 5 years enjoy more protection of about 50% 
reduction [179]. This protection is enjoyed by women of all ages and parities.
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Therefore while HRT is associated with increasing risk, the pills are associated 
with reduced risk a position both have similar active ingredients and estrogen has 
been blamed in ovarian carcinogenesis.
16.4 Hysterectomy/tubal ligation
Observational epidemiologic evidence strongly support tubal ligation and hys-
terectomy to be associated with a decrease in the risk of ovarian cancer, by approxi-
mately 26–30% [184]. Having fallopian tubes tied hysterectomy and unilateral 
oophorectomy may reduce risk by up to 67% [184, 185].
Patients with BRCA1 but not with BRCA2 are found to benefit from the pro-
tection conferred by tubal ligation to OC [186]. Tubal ligation and hysterectomy 
reduce risk of low grade more than high grade serous cancers. Risk of endometrioid 
cancer is almost halved. Tubal ligation is not observed to reduce the risk of muci-
nous tumors [187].
16.5 Physical activity and exercise
Physical activity may be beneficial in both risk reduction of inflammation, 
decreasing body fat and frequency of ovulation. Survivors of ovarian cancer may 
also experience general health benefit of physical activity [188]. The specific 
effect of physical exercise on ovarian cancer in general and the various histologic 
subtypes have shown inconsistent results. The most consistent result obtained 
by research is that of increasing risk by prolonged sedentary life style physical 
inactivity [188, 189].
Considering direct effect of physical activity however, some studies report no 
effect on the risk of ovarian cancer [190, 191] while other studies report risk reduc-
tion [190, 191]. The reduction of risk may be to epithelial cancers. Physical activity 
may not be affecting sex cord-stromal and germ cell cancers of the ovary.
17. Conclusion
The risk of ovarian cancer in women is modified by a number of biologic, hor-
monal, lifestyle and geographic factors the extent of which differs between the histo-
logic varieties. There may be racial or regional variation in the extent to which these 
factor increase risk or protect against particularly the most common histologic subtype.
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